AR098958A1 - Formas cristalinas de un compuesto antiviral antecedentes - Google Patents
Formas cristalinas de un compuesto antiviral antecedentesInfo
- Publication number
- AR098958A1 AR098958A1 ARP140104909A ARP140104909A AR098958A1 AR 098958 A1 AR098958 A1 AR 098958A1 AR P140104909 A ARP140104909 A AR P140104909A AR P140104909 A ARP140104909 A AR P140104909A AR 098958 A1 AR098958 A1 AR 098958A1
- Authority
- AR
- Argentina
- Prior art keywords
- crystal forms
- antiviral compound
- compound background
- background
- compound
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title abstract 2
- 230000000840 anti-viral effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 1
- -1 quinoxaline-8-carboxamide compound Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361920427P | 2013-12-23 | 2013-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR098958A1 true AR098958A1 (es) | 2016-06-22 |
Family
ID=52282995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104909A AR098958A1 (es) | 2013-12-23 | 2014-12-23 | Formas cristalinas de un compuesto antiviral antecedentes |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9562058B2 (enExample) |
| EP (1) | EP3087086B1 (enExample) |
| JP (2) | JP6568541B2 (enExample) |
| AR (1) | AR098958A1 (enExample) |
| AU (1) | AU2014370124A1 (enExample) |
| CA (1) | CA2934049A1 (enExample) |
| ES (1) | ES2708993T3 (enExample) |
| NZ (1) | NZ720887A (enExample) |
| PT (1) | PT3087086T (enExample) |
| TW (1) | TW201609752A (enExample) |
| UY (1) | UY35918A (enExample) |
| WO (1) | WO2015100144A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3087085T3 (pl) | 2013-12-23 | 2019-07-31 | Gilead Sciences, Inc. | Synteza makrocyklicznego tripeptydu hamującego NS3 HCV |
| IL296496B2 (en) | 2014-12-26 | 2024-10-01 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| JOP20170127A1 (ar) | 2016-06-02 | 2017-12-02 | Gilead Pharmasset Llc | صيغة مشتركة مكونة من ثلاث مركبات مضادة للفيروسات |
| KR102626210B1 (ko) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
| CN115417803B (zh) * | 2022-08-30 | 2023-10-03 | 四川同晟生物医药有限公司 | 乌帕替尼中间体(3r,4s)-1-苄氧羰基-4-乙基吡咯烷-3-羧酸的合成方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| CL2008003384A1 (es) * | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
| ME02024B (me) * | 2008-07-22 | 2015-05-20 | Merck Sharp & Dohme | Makrociklična jedinjenja hinoksalina kao inhibitori hcv ns3 proteaze |
| US20130178413A1 (en) * | 2010-09-21 | 2013-07-11 | John A. McCauley | Hcv ns3 protease inhibitors |
| HUE028384T2 (en) * | 2010-09-21 | 2016-12-28 | Enanta Pharm Inc | Macrocyclic proline derived hcv serine protease inhibitors |
| PT2907816T (pt) | 2011-11-16 | 2018-10-18 | Gilead Pharmasset Llc | Imidazolilimidazóis condensados como compostos antivirais |
| UA119315C2 (uk) * | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
-
2014
- 2014-12-18 NZ NZ720887A patent/NZ720887A/en not_active IP Right Cessation
- 2014-12-18 AU AU2014370124A patent/AU2014370124A1/en not_active Abandoned
- 2014-12-18 WO PCT/US2014/071310 patent/WO2015100144A1/en not_active Ceased
- 2014-12-18 ES ES14824322T patent/ES2708993T3/es active Active
- 2014-12-18 JP JP2016560857A patent/JP6568541B2/ja not_active Expired - Fee Related
- 2014-12-18 PT PT14824322T patent/PT3087086T/pt unknown
- 2014-12-18 CA CA2934049A patent/CA2934049A1/en not_active Abandoned
- 2014-12-18 US US14/575,966 patent/US9562058B2/en active Active
- 2014-12-18 EP EP14824322.3A patent/EP3087086B1/en active Active
- 2014-12-22 TW TW103144805A patent/TW201609752A/zh unknown
- 2014-12-23 UY UY0001035918A patent/UY35918A/es not_active Application Discontinuation
- 2014-12-23 AR ARP140104909A patent/AR098958A1/es unknown
-
2016
- 2016-12-21 US US15/387,318 patent/US9862728B2/en active Active
-
2019
- 2019-02-07 JP JP2019020540A patent/JP2019089819A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2708993T3 (es) | 2019-04-12 |
| UY35918A (es) | 2015-05-29 |
| EP3087086A1 (en) | 2016-11-02 |
| PT3087086T (pt) | 2019-02-06 |
| US9862728B2 (en) | 2018-01-09 |
| US20150175625A1 (en) | 2015-06-25 |
| WO2015100144A1 (en) | 2015-07-02 |
| US20170267694A1 (en) | 2017-09-21 |
| AU2014370124A1 (en) | 2016-06-23 |
| EP3087086B1 (en) | 2018-11-07 |
| JP2017503016A (ja) | 2017-01-26 |
| TW201609752A (zh) | 2016-03-16 |
| US9562058B2 (en) | 2017-02-07 |
| JP6568541B2 (ja) | 2019-08-28 |
| JP2019089819A (ja) | 2019-06-13 |
| CA2934049A1 (en) | 2015-07-02 |
| NZ720887A (en) | 2018-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2017005467A (es) | Formas sólidas de un inhibidor ask1. | |
| DK3699181T3 (da) | Krystallinsk form af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamidhydrogensulfat | |
| CL2018001722A1 (es) | Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506) | |
| NZ728072A (en) | Modulators of toll-like receptors for the treatment of hiv | |
| EA201690617A1 (ru) | Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей | |
| TWD169700S (zh) | 針盤 | |
| EA201691473A1 (ru) | Биспецифические анти-il-13/il-17 антитела и их применение | |
| EP3007901A4 (en) | Printing process using soft photopolymer plates | |
| WO2015081085A3 (en) | Methods of treating a tauopathy | |
| EA201690513A1 (ru) | Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний | |
| MX2022014695A (es) | Anticuerpos anti-gitr y sus usos. | |
| DOP2017000288A (es) | Moduladores alostéricos positivos del receptor muscarínico m2. | |
| UY35918A (es) | Formas cristalinas de un compuesto antiviral | |
| MX2016004565A (es) | Preparacion de derivados de hidroxi - bencilbenceno. | |
| UY34976A (es) | Formas sólidas de un compuesto antiviral | |
| BR112015026827A2 (pt) | Formas polimórficas de cloridrato de nilotinibe | |
| WO2014153495A9 (en) | Novel stat3 inhibitors | |
| MX373389B (es) | Derivado de sulfonamida y uso farmaceutico del mismo. | |
| EP3370280A4 (en) | Electrode for secondary battery comprising fine holes | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
| WO2014146111A3 (en) | Analgesic compounds and methods of use | |
| AR100289A1 (es) | Formas de un inhibidor de pi3k | |
| MX2020003730A (es) | Nueva sal y formas en estado solido de escitalopram. | |
| PE20151789A1 (es) | N-(2-fluoro-2-fenetil)carboxamidas como nematicidas y endoparasiticidas | |
| EA201790526A1 (ru) | Фармацевтические комбинации ситаглиптина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |